Wenyan Zhong

23.2k total citations · 1 hit paper
33 papers, 992 citations indexed

About

Wenyan Zhong is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wenyan Zhong has authored 33 papers receiving a total of 992 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wenyan Zhong's work include Cancer Cells and Metastasis (3 papers), Cancer Genomics and Diagnostics (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Wenyan Zhong is often cited by papers focused on Cancer Cells and Metastasis (3 papers), Cancer Genomics and Diagnostics (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Wenyan Zhong collaborates with scholars based in United States, China and United Kingdom. Wenyan Zhong's co-authors include N H Georgopapadakou, Jeremy S. Myers, Marc Damelin, Puja Sapra, Christine Huard, Robert V. Martinez, Janet Paulsen, Heather H. Shih, Stephen J. Benkovic and Edward Rosfjord and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Wenyan Zhong

29 papers receiving 963 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Wenyan Zhong

Since Specialization

Citations

This map shows the geographic impact of Wenyan Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenyan Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenyan Zhong more than expected).

Fields of papers citing papers by Wenyan Zhong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenyan Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenyan Zhong. The network helps show where Wenyan Zhong may publish in the future.

Co-authorship network of co-authors of Wenyan Zhong

This figure shows the co-authorship network connecting the top 25 collaborators of Wenyan Zhong. A scholar is included among the top collaborators of Wenyan Zhong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenyan Zhong. Wenyan Zhong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transformer-based self-supervised learning of pixel- and frequency-domain features for DMI grading on OCTA images 2025 ·Applied Optics ·Zailiang Chen, Wenyan Zhong, Fei Yu, Hailan Shen, (unknown), (unknown), (unknown)	0
2	A Ralstonia solanacearum effector regulates plant cell death by disrupting the homeostasis of the BPA1-ACD11 complex 2025 ·mBio ·(unknown), Yan Zhou, Yue Xie, (unknown), Jinye Zhang, Yang Zhang, Wenyan Zhong, Junlong Zhao, (unknown), Lifang Ruan	0
3	DSDC-NET: Semi-supervised superficial OCTA vessel segmentation for false positive reduction 2025 ·Pattern Recognition ·(unknown), Hailan Shen, Wenyan Zhong, (unknown), Zailiang Chen	0
4	Abstract LB012: Evaluating computational approaches for CPTAC pan-cancer cross-cohort protein expression comparison 2024 ·Cancer Research ·(unknown), Xiaowen Tian, (unknown), (unknown), Elaine M. Hurt, Wenyan Zhong	0
5	A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394 2024 ·Liver Cancer ·Shukui Qin, Weijia Fang, Zhenggang Ren, Shuangyan Ou, Ho Yeong Lim, Feng Zhang, (unknown), Hye Jin Choi, Jiandong Tong, (unknown), (unknown), Ashley Cheng, Chang‐Hsien Lu, (unknown), (unknown), Shital Kamble, Josephine M. Norquist, Wenyan Zhong, Chen Li, Zhendong Chen	7
6	Pan-Cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics 2023 ·Molecular & Cellular Proteomics ·(unknown), (unknown), (unknown), (unknown), Matthew E. Wilson, Matthew Sung, (unknown), Elaine M. Hurt, Gina D’Angelo, Ben S. Sidders, Zhongwu Lai, Wenyan Zhong	4
7	Abstract LB227: Leveraging novel Dato-DXd resistance models to inform biomarker discovery and rational combinations to combat drug resistance 2023 ·Cancer Research ·(unknown), Chetan K. Rane, Gopi Patel, Deepa Bhavsar, Shenghua Wen, David Clark, Yeoun Jin Kim, Alan Lau, Yann Wallez, (unknown), Wenyan Zhong, Matthew Sung	3
8	Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial breakdown → 2022 ·Journal of Clinical Oncology ·Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek‐Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaohong Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao	127
9	GeneTEFlow: A Nextflow-based pipeline for analysing gene and transposable elements expression from RNA-Seq data 2020 ·PLoS ONE ·Xiaochuan Liu, Jadwiga Biénkowska, Wenyan Zhong	3
10	Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors 2020 ·BMC Genomics ·Wenyan Zhong, Jeremy S. Myers, Fang Wang, Kai Wang, Justin Lucas, Edward Rosfjord, Judy Lucas, Andrea T. Hooper, Sharon Yang, (unknown), Magali Guffroy, Chad May, Jadwiga Biénkowska, Paul A. Rejto	113
11	Prevalence, risk factors and genotype distribution of Toxoplasma gondii DNA in soil in China 2019 ·Ecotoxicology and Environmental Safety ·Wei Cong, Nian‐Zhang Zhang, Rui-Si Hu, Feng‐Cai Zou, Yang Zou, Wenyan Zhong, Jingjing Wu, (unknown), Xing‐Quan Zhu, Hany M. Elsheikha	22
12	Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients 2017 ·PLoS ONE ·Steven Pirie‐Shepherd, Cory L. Painter, Pamela Whalen, (unknown), Marc D. Roy, (unknown), (unknown), (unknown), (unknown), Shibing Deng, Wenyan Zhong, (unknown), Dena Marrinucci, Hans‐Peter Gerber, Eric L. Powell	7
13	Breast Cancer Cells Respond Differentially to Modulation of TGFβ2 Signaling after Exposure to Chemotherapy or Hypoxia 2015 ·Cancer Research ·(unknown), Liang Chen, Wenyan Zhong, Douglas Armellino, Jiyang Yu, Christine Loreth, Maximillian T. Follettie, Marc Damelin	9
14	Evolving Strategies for Target Selection for Antibody-Drug Conjugates 2015 ·Pharmaceutical Research ·Marc Damelin, Wenyan Zhong, Jeremy S. Myers, Puja Sapra	110
15	Estrogen-related receptor α regulates osteoblast differentiation via Wnt/β-catenin signaling 2012 ·Journal of Molecular Endocrinology ·(unknown), Stephen P. Berasi, Yan Liu, (unknown), Ying Zhang, Christine Huard, Shoichi Fukayama, Jing Zhang, Sung Choe, Wenyan Zhong, Bheem M. Bhat, Ramesh A. Bhat, Eugene L. Brown, Robert V. Martinez	45
16	LOX-1-dependent transcriptional regulation in response to oxidized LDL treatment of human aortic endothelial cells 2009 ·American Journal of Physiology-Cell Physiology ·(unknown), Christine Huard, Wei Cao, Andrew A. Hill, Wenyan Zhong, Robert V. Martinez, (unknown), Janet Paulsen, Heather H. Shih	55
17	LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse 2009 ·Journal of Lipid Research ·Elaine Quinet, Michael Basso, Anita Halpern, David Yates, Robert J. Steffan, Valérie Clerin, Christine Resmini, James C. Keith, Thomas J. Berrodin, Irene Feingold, Wenyan Zhong, Helen B. Hartman, Mark J. Evans, Stephen J. Gardell, Elizabeth A. DiBlasio-Smith, William Mounts, Edward R. LaVallie, Jay Wrobel, Ponnal Nambi, George P. Vlasuk	82
18	Transcriptional profiling of C2C12 myotubes in response to SHIP2 depletion and insulin stimulation 2006 ·Genomics ·Christine Huard, Robert V. Martinez, (unknown), Jeremy Johnson, Wenyan Zhong, Andrew A. Hill, Richard Kim, Janet Paulsen, Heather H. Shih	7
19	Inhibition of yeast inositol phosphorylceramide synthase by aureobasidin A measured by a fluorometric assay 1999 ·FEBS Letters ·Wenyan Zhong, Dennis J. Murphy, N H Georgopapadakou	29
20	Development of an Internally Quenched Fluorescent Substrate forEscherichia coliLeader Peptidase 1998 ·Analytical Biochemistry ·Wenyan Zhong, Stephen J. Benkovic	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact